BMO Capital Markets has lowered the price target for Abbot Laboratories (NYSE:ABT) to US$48.00 from US$56.00 a share before Monday’s market opening.
Abbott Laboratories (NYSE:ABT) is also Reiterated by RBC Capital Markets to Outperform according to the research report released to the investors. The Brokerage Firm has Lowered the Price Target of the company shares to $51 from a previous price target of $55 .
Shares of Abbot Laboratories were trading 1.82 percent higher on pre-opening at 41.91 apiece. The stock has a price range of 40.94-41.98.
On Friday, Abbot Laboratories (NYSE:ABT)’s stock began at $41.07 and was seen hitting $41.98 as a peak level and $40.94 as the lowest level. The stock ended up at $41.89. The daily volume was measured at 10,400,179 shares. The 52-week high of the share price is $51.74 and the 52-week low is $39. The company has a market cap of $62,435 million.
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products.
Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. – BusinessNewsAsia.com